Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA (CLPTM1L)
- Development stage
- Preclinical
- Lead developer
- Essential Biotechnology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
siRNA (CLPTM1L) is a therapeutic candidate utilizing small interfering RNA (siRNA) technology to target the Cleft Lip and Palate Transmembrane 1-Like protein (CLPTM1L). CLPTM1L is an endoplasmic reticulum (ER) stress-inducible oncofetal protein that is overexpressed on the plasma membrane of multiple myeloma cells and associated with chemoresistance. By silencing CLPTM1L expression, this siRNA inhibits the AKT signaling pathway, leading to the downregulation of anti-apoptotic proteins (BCL2, BCLXL) and the upregulation of pro-apoptotic markers (cleaved caspase-3, BID, cleaved PARP). Preclinical studies indicate that CLPTM1L knockdown sensitizes myeloma cells to proteasome inhibitors such as bortezomib, suggesting its potential as a combination therapy for resistant blood cancers.
- Other names
- CLPTM1L siRNACLPTM-1L siRNACLPTM 1L siRNA
02
Targets
CLPTM1L (Cleft lip and palate transmembrane protein 1-like protein)
Beyond the preview
Go deeper on siRNA (CLPTM1L).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA (CLPTM1L).